

**Ingredion Incorporated**  
**Condensed Consolidated Statements of Income**  
**(Unaudited)**

(in millions, except per share amounts)

	Three Months Ended September 30,		Change %	Nine Months Ended September 30,		Change %
	2022	2021		2022	2021	
Net sales	\$ 2,023	\$ 1,763	15%	\$ 5,959	\$ 5,139	16%
Cost of sales	1,649	1,440		4,816	4,098	
Gross profit	374	323	16%	1,143	1,041	10%
Operating expenses	180	164	10%	528	484	9%
Other operating expense (income)	10	(1)		4	(29)	
Restructuring/impairment charges and related adjustments	2	(12)		6	362	
Operating income	182	172	6%	605	224	170%
Financing costs	24	20		65	58	
Other non-operating (income)	(3)	(1)		(4)	(4)	
Income before income taxes	161	153	5%	544	170	220%
Provision for income taxes	52	34		157	113	
Net income	109	119	(8%)	387	57	579%
Less: Net income attributable to non-controlling interests	3	1		9	7	
Net income attributable to Ingredion	\$ 106	\$ 118	(10%)	\$ 378	\$ 50	656%

Earnings per common share attributable to Ingredion common shareholders:

Weighted average common shares outstanding:

Basic	65.8	67.0		66.4	67.2	
Diluted	66.6	67.6		67.1	67.8	

Earnings per common share of Ingredion:

Basic	\$ 1.61	\$ 1.76	(9%)	\$ 5.69	\$ 0.74	669%
Diluted	\$ 1.59	\$ 1.75	(9%)	\$ 5.63	\$ 0.74	661%

**Ingredion Incorporated**  
**Condensed Consolidated Balance Sheets**

(in millions, except share and per share amounts)

	<u>September 30, 2022</u> (Unaudited)	<u>December 31, 2021</u>
<b>Assets</b>		
Current assets		
Cash and cash equivalents	\$ 294	\$ 328
Short-term investments	4	4
Accounts receivable – net	1,406	1,130
Inventories	1,500	1,172
Prepaid expenses	64	63
<b>Total current assets</b>	<b>3,268</b>	<b>2,697</b>
Property, plant and equipment – net	2,308	2,423
Intangible assets – net	1,286	1,348
Other assets	541	531
<b>Total assets</b>	<b>\$ 7,403</b>	<b>\$ 6,999</b>
<b>Liabilities and equity</b>		
Current liabilities		
Short-term borrowings	\$ 709	\$ 308
Accounts payable and accrued liabilities	1,240	1,204
<b>Total current liabilities</b>	<b>1,949</b>	<b>1,512</b>
Long-term debt	1,739	1,738
Other non-current liabilities	536	524
<b>Total liabilities</b>	<b>4,224</b>	<b>3,774</b>
Share-based payments subject to redemption	43	36
Redeemable non-controlling interests	56	71
Equity		
Ingredion stockholders' equity:		
Preferred stock – authorized 25,000,000 shares – \$0.01 par value, none issued	-	-
Common stock – authorized 200,000,000 shares – \$0.01 par value, 77,810,875 shares issued at September 30, 2022 and December 31, 2021	1	1
Additional paid-in capital	1,133	1,158
Less: Treasury stock (common stock; 12,258,900 and 11,154,203 shares at September 30, 2022 and December 31, 2021, respectively) at cost	(1,159)	(1,061)

Accumulated other comprehensive loss	(1,052)	(897)
Retained earnings	4,143	3,899
Total Ingredient stockholders' equity	3,066	3,100
Non-redeemable non-controlling interests	14	18
Total equity	3,080	3,118
<b>Total liabilities and equity</b>	<b>\$ 7,403</b>	<b>\$ 6,999</b>

**Ingredion Incorporated**  
**Condensed Consolidated Statements of Cash Flows**  
**(Unaudited)**

(in millions)	Nine Months Ended September 30,	
	2022	2021
<b>Cash provided by operating activities:</b>		
Net income	\$ 387	\$ 57
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	160	155
Mechanical stores expense	42	40
Impairment on disposition of assets	-	340
Deferred income taxes	(3)	(25)
Margin accounts	(11)	(34)
Changes in other trade working capital	(578)	(258)
Other	83	(16)
Cash provided by operating activities	80	259
<b>Cash used for investing activities:</b>		
Capital expenditures and mechanical stores purchases	(203)	(203)
Proceeds from disposal of manufacturing facilities and properties	7	17
Payments for acquisitions, net of cash acquired	(7)	(40)
Other	1	(12)
Cash used for investing activities	(202)	(238)
<b>Cash provided by (used for) financing activities:</b>		
Proceeds from (payments on) borrowings, net	34	(390)
Commercial paper borrowings, net	372	350
Repurchases of common stock, net	(112)	(68)
Purchases of non-controlling interests	(40)	-

Issuances of common stock for share-based compensation, net of settlements		1		10
Dividends paid, including to non-controlling interests		(133)		(138)
Cash provided by (used for) financing activities		122		(236)
Effect of foreign exchange rate changes on cash		(34)		(16)
Decrease in cash and cash equivalents		(34)		(231)
Cash and cash equivalents, beginning of period		328		665
Cash and cash equivalents, end of period	\$	294	\$	434

**Ingredion Incorporated**  
**Supplemental Financial Information**  
**(Unaudited)**

**I. Geographic Information of Net Sales and Operating Income**

(in millions, except for percentages)

	<b>Three Months Ended September 30,</b>		<b>Change</b>	<b>Change Excl. FX</b>	<b>Nine Months Ended September 30,</b>		<b>Change</b>	<b>Change Excl. FX</b>
	<b>2022</b>	<b>2021</b>			<b>2022</b>	<b>2021</b>		
Net Sales								
North America	\$ 1,262	\$ 1,083	17%	17%	\$ 3,720	\$ 3,096	20%	20%
South America	293	260	13%	16%	835	801	4%	4%
Asia-Pacific	278	245	13%	23%	825	728	13%	21%
EMEA	190	175	9%	27%	579	514	13%	26%
Total Net Sales	\$ 2,023	\$ 1,763	15%	19%	\$ 5,959	\$ 5,139	16%	19%
Operating Income								
North America	\$ 126	\$ 120	5%	5%	\$ 443	\$ 403	10%	10%
South America	48	35	37%	43%	125	108	16%	16%
Asia-Pacific	27	21	29%	43%	70	70	0%	10%
EMEA	30	23	30%	52%	90	86	5%	20%
Corporate	(40)	(36)	(11%)	(11%)	(109)	(95)	(15%)	(15%)
Sub-total	191	163	17%	23%	619	572	8%	12%
Acquisition/integration costs	-	(3)			(1)	(1)		
Restructuring/impairment charges	-	(8)			(4)	(22)		
Impairment on disposition of assets	-	20			-	(340)		
Other matters	(9)	-			(9)	15		
Total Operating Income	\$ 182	\$ 172	6%	12%	\$ 605	\$ 224	170%	179%

## II. Non-GAAP Information

To supplement the consolidated financial results prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), we use non-GAAP historical financial measures, which exclude certain GAAP items such as acquisition and integration costs, restructuring and impairment costs, Mexico tax (benefit) provision, and other specified items. We generally use the term “adjusted” when referring to these non-GAAP amounts.

Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a more meaningful, consistent comparison of our operating results and trends for the periods presented. These non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and reflect an additional way of viewing aspects of our operations that, when viewed with our GAAP results, provide a more complete understanding of factors and trends affecting our business. These non-GAAP measures should be considered as a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP.

Non-GAAP financial measures are not prepared in accordance with GAAP; so our non-GAAP information is not necessarily comparable to similarly titled measures presented by other companies. A reconciliation of each non-GAAP financial measure to the most comparable GAAP measure is provided in the tables below.

**Ingredion Incorporated**  
**Reconciliation of GAAP Net Income attributable to Ingredion and Diluted Earnings Per Share (“EPS”) to**  
**Non-GAAP Adjusted Net Income attributable to Ingredion and Adjusted Diluted EPS**  
**(Unaudited)**

	Three Months Ended September 30, 2022		Three Months Ended September 30, 2021		Nine Months Ended September 30, 2022		Nine Months Ended September 30, 2021	
	(in millions)	Diluted EPS	(in millions)	Diluted EPS	(in millions)	Diluted EPS	(in millions)	Diluted EPS
Net income attributable to Ingredion	\$ 106	\$ 1.59	\$ 118	\$ 1.75	\$ 378	\$ 5.63	\$ 50	\$ 0.74
Add back:								
Acquisition/integration costs, net of \$ - million of income taxes for the three and nine months ended September 30, 2022, and inclusive of \$ - million and \$4 million of income tax expense for the three and nine months ended September 30, 2021, respectively (i)	-	-	4	0.06	1	0.01	6	0.09
Restructuring/impairment charges, net of \$ - million and \$1 million of income tax benefit for the three and nine months ended September 30, 2022, respectively and \$1 million and \$5 million for the three and nine months ended September 30, 2021, respectively (ii)	-	-	7	0.10	3	0.05	17	0.25
Impairment on disposition of assets, net of \$ - million of income tax benefit for the three and nine months ended September 30, 2021 (iii)	-	-	(20)	(0.30)	-	-	340	5.02
Other matters, net of income tax expense of \$2 million for the three and nine months ended September 30, 2022, and \$ - million and \$5 million for the three and nine months ended September 30, 2021, respectively (iv)	7	0.11	-	-	7	0.11	(10)	(0.15)

Tax (benefit) provision - Mexico (v)	(1)	(0.02)	5	0.07	(2)	(0.03)	4	0.06
Other tax matters (vi)	3	0.05	(1)	(0.01)	2	0.03	(29)	(0.43)
Non-GAAP adjusted net income attributable to Ingredion	\$ 115	\$ 1.73	\$ 113	\$ 1.67	\$ 389	\$ 5.80	\$ 378	\$ 5.58

*Net income, EPS and tax rates may not foot or recalculate due to rounding.*

#### Notes

(i) During the nine months ended September 30, 2022, we recorded \$1 million of pre-tax acquisition and integration charges related to our acquisition and integration of KaTech, as well as our investment in the Argentina joint venture.

During the three and nine months ended September 30, 2021, we recorded \$3 million and \$1 million of pre-tax net acquisition and integration charges, respectively, related to our investments in the Amyris and Argentina joint ventures, as well as our acquisition of PureCircle Limited.

(ii) During the nine months ended September 30, 2022, we recorded \$4 million of remaining pre-tax restructuring-related charges for the Cost Smart program.

During the three and nine months ended September 30, 2021, we recorded pre-tax restructuring-related charges of \$8 million and \$22 million, respectively, primarily related to our Cost Smart programs. The \$22 million of charges for the nine months ended September 30, 2022 are net of a \$5 million gain on the sale of Stockton, California land and building that occurred during the second quarter of 2021.

(iii) During the nine months ended September 30, 2021, we recorded a \$340 million net asset impairment charge related to the contribution of Ingredion's Argentina operations to the Argentina joint venture. The impairment charge reflected a \$29 million write-down to the agreed upon fair value of certain Argentina, Chile and Uruguay assets and liabilities contributed and a \$311 million write-off of the cumulative translation losses related to the contributed net assets. During the three months ended September 30, 2021, we recorded a \$20 million favorable adjustment to the impairment upon finalization of the transaction, which reduced the \$360 million asset impairment charge recorded during the first quarter of 2021.

(iv) During the three months ended September 30, 2022, we recorded pre-tax charges of \$9 million primarily related to the impacts of a U.S.-based work stoppage.

During the nine months ended September 30, 2021, we recorded a pre-tax benefit of \$15 million to reflect a ruling the Brazilian Supreme Court issued in May 2021 that affirmed that we were entitled to certain indirect taxes.

(v) We recorded tax benefits of \$1 million and \$2 million for the three and nine months ended September 30, 2022, respectively, and tax provisions of \$5 million and \$4 million for the three and nine months ended September 30, 2021, respectively, as a result of the movement of the Mexican peso against the U.S. dollar and its impact on the remeasurement of the Company's Mexico financial statements during the periods.

(vi) This item relates to prior year tax liabilities and contingencies, the reversal of tax liabilities related to certain unremitted earnings from foreign subsidiaries, and tax results of the above non-GAAP addbacks.

**Reconciliation of GAAP Operating Income to Non-GAAP Adjusted Operating Income  
(Unaudited)**

(in millions, pre-tax)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2022	2021	2022	2021
Operating income	\$ 182	\$ 172	\$ 605	\$ 224
Add back:				
Acquisition/integration costs (i)	-	3	1	1
Restructuring/impairment charges (ii)	-	8	4	22
Impairment on disposition of assets (iii)	-	(20)	-	340
Other matters (iv)	9	-	9	(15)
Non-GAAP adjusted operating income	\$ 191	\$ 163	\$ 619	\$ 572

For notes (i) through (iv), see notes (i) through (iv) included in the Reconciliation of GAAP Net Income attributable to Ingredion and Diluted EPS to Non-GAAP Adjusted Net Income attributable to Ingredion and Adjusted Diluted EPS.

**II. Non-GAAP Information (continued)**

**Ingredion Incorporated  
Reconciliation of GAAP Effective Income Tax Rate to Non-GAAP Adjusted Effective Income Tax Rate  
(Unaudited)**

(in millions)	Three Months Ended September 30, 2022			Nine Months Ended September 30, 2022		
	Income before Income Taxes (a)	Provision for Income Taxes (b)	Effective Income Tax Rate (b / a)	Income before Income Taxes (a)	Provision for Income Taxes (b)	Effective Income Tax Rate (b / a)
As Reported	\$ 161	\$ 52	32.3%	\$ 544	\$ 157	28.9%

Add back:						
Acquisition/integration costs (i)	-	-		1	-	
Restructuring/impairment charges (ii)	-	-		4	1	
Other matters (iv)	9	2		9	2	
Tax item - Mexico (v)	-	1		-	2	
Other tax matters (vi)	-	(3)		-	(2)	
Adjusted Non-GAAP	<u>\$ 170</u>	<u>\$ 52</u>	30.6%	<u>\$ 558</u>	<u>\$ 160</u>	28.7%

(in millions)	Three Months Ended September 30, 2021			Nine Months Ended September 30, 2021		
	Income before Income Taxes (a)	Provision for Income Taxes (b)	Effective Income Tax Rate (b / a)	Income before Income Taxes (a)	Provision for Income Taxes (b)	Effective Income Tax Rate (b / a)
As Reported	\$ 153	\$ 34	22.2%	\$ 170	\$ 113	66.5%
Add back:						
Acquisition/integration costs (i)	3	-		1	(4)	
Restructuring/impairment charges (ii)	8	1		22	5	
Impairment on disposition of assets (iii)	(20)	-		340	-	
Other matters (iv)	-	-		(15)	(5)	
Tax item - Mexico (v)	-	(5)		-	(4)	
Other tax matters (vi)	-	1		-	29	
Adjusted Non-GAAP	<u>\$ 144</u>	<u>\$ 31</u>	21.5%	<u>\$ 518</u>	<u>\$ 134</u>	25.9%

For notes (i) through (vi), see notes (i) through (vi) included in the Reconciliation of GAAP Net Income attributable to Ingredion and Diluted EPS to Non-GAAP Adjusted Net Income attributable to Ingredion and Adjusted Diluted EPS.



## II. Non-GAAP Information (continued)

**Ingredion Incorporated**  
**Reconciliation of Expected GAAP Diluted Earnings per Share (“GAAP EPS”)**  
**to Expected Adjusted Diluted Earnings per Share (“Adjusted EPS”)**  
**(Unaudited)**

	Expected EPS Range for Full-Year 2022	
	<u>Low End of Guidance</u>	<u>High End of Guidance</u>
GAAP EPS	\$ 6.90	\$ 7.20
Add:		
Acquisition/integration costs (i)	0.01	0.01
Restructuring/impairment charges (ii)	0.05	0.05
Other matters (iii)	0.11	0.11
Tax item - Mexico (iv)	(0.10)	0.05
Other tax matters (v)	0.03	0.03
Adjusted EPS	<u>\$ 7.00</u>	<u>\$ 7.45</u>

Above is a reconciliation of our expected full-year 2022 diluted EPS to our expected full-year 2022 adjusted diluted EPS. The amounts above may not reflect certain future charges, costs and/or gains that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance. These amounts include, but are not limited to, adjustments to GAAP EPS for acquisition and integration costs, impairment and restructuring costs, and certain other items. We generally exclude these adjustments from our adjusted EPS guidance. For these reasons, we are more confident in our ability to forecast adjusted EPS than we are in our ability to forecast GAAP EPS.

These adjustments to GAAP EPS for 2022 include the following:

- (i) Acquisition and integration charges for our acquisition and integration of KaTech, as well as our investment in the Argentina joint venture.
- (ii) Remaining restructuring-related charges for the Cost Smart programs.
- (iii) Charges to date primarily related to the impacts of a U.S.-based work stoppage.

(iv) Tax (benefit) expense as a result of the movement of the Mexican peso against the U.S. dollar and its impact on the remeasurement of the Company's Mexico financial statements during the period.

(v) This item relates to prior year tax liabilities and contingencies.

## II. Non-GAAP Information (continued)

**Ingredion Incorporated**  
**Reconciliation of Expected U.S. GAAP Effective Tax Rate ("GAAP ETR")**  
**to Expected Adjusted Effective Tax Rate ("Adjusted ETR")**  
**(Unaudited)**

	Expected Effective Tax Rate Range for Full-Year 2022	
	Low End of Guidance	High End of Guidance
GAAP ETR	28.0 %	31.5 %
Add:		
Acquisition/integration costs (i)	- %	- %
Restructuring/impairment charges (ii)	0.2 %	0.2 %
Other matters (iii)	0.3 %	0.3 %
Tax item - Mexico (iv)	1.0 %	(1.5) %
Other Tax Matters (v)	(0.2) %	(0.2) %
Impact of adjustment on Effective Tax Rate (vi)	(0.8) %	(0.8) %
Adjusted ETR	28.5 %	- 29.5 %

Above is a reconciliation of our expected full-year 2022 GAAP ETR to our expected full-year 2022 adjusted ETR. The amounts above may not reflect certain future charges, costs and/or gains that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance. These amounts include, but are not limited to, adjustments to GAAP ETR for acquisition and integration costs, impairment and restructuring costs, and certain other items. We generally exclude these adjustments from our adjusted ETR guidance. For these reasons, we are more confident in our ability to forecast adjusted ETR than we are in our ability to forecast GAAP ETR.

These adjustments to GAAP ETR for 2022 include the following:

- (i) Tax impact on acquisition and integration charges for our acquisition and integration of KaTech, as well as our investment in the Argentina joint venture.
- (ii) Tax impact on remaining restructuring-related charges for the Cost Smart programs.
- (iii) Tax impact primarily on charges to date related to the impacts of a U.S.-based work stoppage.
- (iv) Tax benefit (expense) as a result of the movement of the Mexican peso against the U.S. dollar and its impact to the remeasurement of the Company's Mexico financial statements during the periods.
- (v) This item relates to prior year tax liabilities and contingencies.
- (vi) Indirect impact of tax rate after items (i), (ii), and (iii).